As President Donald Trump renewed his threat of potential pharmaceutical tariffs this week, trade group the Biotechnology Innovation Organization is warning of the fallout the additional duties could have on patients’ access to medicines. More: Drugmakers fear Trump tariffs will
read moreIn an untitled letter issued last Friday and made public this week, the FDA took aim at clinical data included on a doctor-facing web page for Taiho Oncology’s Lytgobi. More: FDA calls out 'particularly concerning' claims on HCP site for
read moreAspen Biopharma Labs was hit with a warning letter from the FDA outlining multiple issues at an API facility in India, including poor building design that could lead to drug contamination. More: India's Aspen Biopharma Labs hit with FDA warning
read moreATyr Pharma is stepping up its preparations to launch a steroid-sparing drug with the appointment of a commercial head who previously helped ChemoCentryx communicate a similar value proposition en route to its acquisition by Amgen. More: ATyr hires ex-ChemoCentryx commercial
read more
NOUS-209 shows potential to intercept cancer in its early stages More: Nouscom reveals promising results for lynch syndrome immunotherapy Source: News
read moreGilead’s HIV portfolio likely won’t feel too big of an impact from potential reductions in the U.S. government’s HIV prevention budget, although changes to the government’s Medicaid spending bill may be something to watch out for, analysts at Jefferies said.
read more© 1994 - 2026 B.M. Pharmaceuticals